
Third death reported with a Sarepta gene therapy
A third fatality has been recorded among patients receiving treatment with a Sarepta gene therapy, adding to the troubles being faced by the company.

BMS, Pfizer take DTC route for blood thinner Eliquis
BMS, Pfizer launch direct-to-patient sales for anticoagulant Eliquis, as a report cites conflict-of-interest concerns about the emerging DTC channel.

GSK's growth plans dented by Blenrep setback
FDA advisors have voted that the benefit/risk profile of GSK's multiple myeloma therapy, Blenrep, does not support its approval in the US.

UK plans to invest 'billions' in Essex biosecurity centre
The UK government has revealed a plan to open a multibillion-pound biosecurity facility to protect the country from emerging public health threats.

Medical chatbot firm OpenEvidence raises $210m
OpenEvidence has raised $210m to expand the capabilities of its physician decision-making tool and launch a new service offering 'PhD-level' research.
Partner Content

2nd Hit ID Summit
Why prioritise your hit discovery game? Finding the right chemical start points is crucial to help you save time and costs in the long run.

Unlocking the Potential of Targeting the Innate Immune Syste...
Ready to Catalyze the Next Wave of Inflammasome Therapies?

The Inaugural Market Access for CNS Therapeutics Summit Has ...
The only dedicated forum focused on tackling the unique commercial and reimbursement challenges facing treatments for neurodegeneration...

5th Oligonucleotides for CNS Summit
The Oligonucleotides for CNS Summit returns for its 5th year to address key challenges in durability, scalability, potency and CNS tropism

Immune Cell Engager Partnering & Investment Summit
Driving high ROI across immune cell engagers through strategic partnerships & investments, capitalizing on novel targets & asset tunability...